EUVIMEDEUVIMED entdecken
Crossref

Upper tract surveillance of patients with high-risk non-muscle invasive bladder cancer: A risk-stratified approach for detecting upper tract urothelial carcinoma recurrence based on long-term follow-up data

Rebecca Smith, Helena Burden, Jennifer Martin, Yamin P. P. Lin, Katherine Warren

Journal of Clinical Urology · 26.06.2026

DOI: 10.1177/20514158261458151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Urology, online erschienen am 26.06.2026. Verfasst von Rebecca Smith und 4 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To propose a surveillance approach for upper tract urothelial carcinoma (UTUC) recurrence in high-risk and very high-risk non-muscle invasive bladder cancer (HR NMIBC) patients.

Method

Retrospective analysis in 2024 of 317 patients diagnosed with HR NMIBC in our centre between 2008 and 2018, including histology, CT urogram (CTU) frequency, radiation dose, UTUC recurrence, outcome, and risk factors for UTUC recurrence.

Results

A total of 283 patients were included for analysis. Incidence of UTUC recurrence 5.7% ( n = 16/283), with 3.5% ( n = 10/283) undergoing nephroureterectomy. Mean time from initial diagnosis to UTUC recurrence is 5.2 years. At 5- and 10-year follow-up, UTUC incidence was 3.5% and 2.1%, respectively. No patients diagnosed with UTUC recurrence beyond 10 years. Patients underwent mean 2.2 surveillance CTU every 1.9 years, with 17.7 mSv mean radiation dose per scan. No significant increased risk of UTUC recurrence associated with carcinoma in situ (CIS) at diagnosis (χ 2 = 0.006, p value = 0.94). Risk of UTUC recurrence significantly increased in patients with recurrent HR NMIBC (27%) versus those without (4%) (relative risk = 7.12, χ 2 = 20.9, p value < 0.00001).

Conclusion

Consider surgical fitness and HR NMIBC recurrence status when determining duration of surveillance for patients. We propose biennial CTU in patients fit for nephroureterectomy, continuing up to 10 years if recurrent HR NMIBC, or up to 5 years if recurrence-free. Level of evidence: 2b – Retrospective cohort study

Zitieren

APA

Smith, R., Burden, H., Martin, J., Lin, Y. P. P., & Warren, K. (2026). Upper tract surveillance of patients with high-risk non-muscle invasive bladder cancer: A risk-stratified approach for detecting upper tract urothelial carcinoma recurrence based on long-term follow-up data. Journal of Clinical Urology. https://doi.org/10.1177/20514158261458151

Vancouver

Smith R, Burden H, Martin J, Lin YPP, Warren K. Upper tract surveillance of patients with high-risk non-muscle invasive bladder cancer: A risk-stratified approach for detecting upper tract urothelial carcinoma recurrence based on long-term follow-up data. Journal of Clinical Urology. 2026. doi:10.1177/20514158261458151

BibTeX
@article{Smith2026,
  author = {Smith, Rebecca and Burden, Helena and Martin, Jennifer and Lin, Yamin P. P. and Warren, Katherine},
  title = {Upper tract surveillance of patients with high-risk non-muscle invasive bladder cancer: A risk-stratified approach for detecting upper tract urothelial carcinoma recurrence based on long-term follow-up data},
  journal = {Journal of Clinical Urology},
  year = {2026},
  doi = {10.1177/20514158261458151}
}
Kostenlos starten →